Unfractionated heparin
Pre-clinicalRecruiting 0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary PCI
Conditions
Primary PCI, ST-elevation Myocardial Infarction (STEMI)
Trial Timeline
Aug 13, 2025 → Apr 1, 2030
NCT ID
NCT07361783About Unfractionated heparin
Unfractionated heparin is a pre-clinical stage product being developed by Sinopharm for Primary PCI. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07361783. Target conditions include Primary PCI, ST-elevation Myocardial Infarction (STEMI).
What happened to similar drugs?
20 of 20 similar drugs in Primary PCI were approved
Approved (20) Terminated (6) Active (0)
Hype Score Breakdown
Clinical
3
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07361783 | Pre-clinical | Recruiting |
Competing Products
20 competing products in Primary PCI